[HTML][HTML] Whole transcriptome analysis of platelet concentrates during storage
H Heililahong, P Jin, H Lei, H Gu, B Qian… - Blood …, 2023 - ncbi.nlm.nih.gov
Background Platelets are anucleated blood cells and contain various RNA species. We
investigated the changes in the whole transcriptome expression profile of platelet concentrates (…
investigated the changes in the whole transcriptome expression profile of platelet concentrates (…
2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests
…, T Jiang, L Fan, H Lei, Y Wang, H Heililahong… - …, 2021 - Taylor & Francis
Objectives Treating red blood cells (RBCs) with dithiothreitol (DTT) is a wildly-recommended
to overcome the interference of the daratumumab (DARA) with blood compatibility testing. …
to overcome the interference of the daratumumab (DARA) with blood compatibility testing. …
Molecular biology analysis of ABO blood group variants caused by natural chimaerism
Y Wang, Q Mou, H Lei, H Heililahong, W Zou… - Vox …, 2022 - Wiley Online Library
Background and Objectives The chimaerism phenomenon constitutes a significant
mechanism underlying ABO phenotype discrepancies; however, its detection has technical …
mechanism underlying ABO phenotype discrepancies; however, its detection has technical …
2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests
…, L Chen, T Jiang, L Fan, H Lei, Y Wang, H Heililahong… - medRxiv, 2020 - medrxiv.org
Background Treating red blood cells (RBCs) with dithiothreitol (DTT) is a wildly-recommended
to overcome the interference of anti-CD38 immunotherapy with blood compatibility testing…
to overcome the interference of anti-CD38 immunotherapy with blood compatibility testing…
F(ab′)2 Fragments to Overcome Daratumumab Interference in Transfusion Tests
K Selleng, PD Gebicka, T Thiele - New England Journal of …, 2018 - Mass Medical Soc
False Positive Coombs’ Tests and Daratumumab Daratumumab is an effective agent in
multiple myeloma. Its binding of CD38 on red cells causes false positive results on Coombs’ …
multiple myeloma. Its binding of CD38 on red cells causes false positive results on Coombs’ …